Epratuzumab is another CD22 monoclonal antibody that has been studied in R/R ALL and investigated as part of a salvage therapy regimen both as a single-agent and in combination with standard reinduction chemotherapy [7]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.